Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CURRNASDAQ:KRRONASDAQ:KYTXNASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURRCURRENC Group$0.50-1.0%$1.20$0.44▼$13.59$23.26M-0.493.57 million shs740,586 shsKRROKorro Bio$12.09+1.3%$14.91$10.29▼$98.00$113.54M2.66107,883 shs99,077 shsKYTXKyverna Therapeutics$2.82+1.1%$2.15$1.78▼$16.64$121.88M2.52417,224 shs94,006 shsSGMTSagimet Biosciences$4.13+13.8%$2.97$1.73▼$7.38$126.69M2.32927,516 shs18.61 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURRCURRENC Group-15.14%+3.59%-64.19%-76.52%+50,489,900.00%KRROKorro Bio+10.46%-6.94%-43.00%-45.70%-76.37%KYTXKyverna Therapeutics+5.28%+8.14%+22.37%+4.89%-78.65%SGMTSagimet Biosciences+4.01%+8.04%-5.22%-0.82%-29.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCURRCURRENC GroupN/AN/AN/AN/AN/AN/AN/AN/AKRROKorro Bio2.465 of 5 stars4.60.00.00.03.20.00.6KYTXKyverna Therapeutics1.6643 of 5 stars3.61.00.00.02.01.70.0SGMTSagimet Biosciences2.4686 of 5 stars3.43.00.00.02.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURRCURRENC Group 3.50Strong Buy$3.50600.00% UpsideKRROKorro Bio 3.29Buy$102.43747.22% UpsideKYTXKyverna Therapeutics 3.14Buy$18.50556.03% UpsideSGMTSagimet Biosciences 2.80Moderate Buy$22.40442.37% UpsideCurrent Analyst Ratings BreakdownLatest CURR, SGMT, KYTX, and KRRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $5.005/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/3/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $4.004/1/2025KYTXKyverna TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $20.003/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/19/2025KRROKorro BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURRCURRENC Group$43.39M0.54N/AN/AN/A∞KRROKorro Bio$4.82M23.55N/AN/A$21.19 per share0.57KYTXKyverna Therapeutics$7.03M17.34N/AN/AN/A∞SGMTSagimet Biosciences$2M63.34N/AN/A$3.98 per share1.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURRCURRENC GroupN/AN/A0.00∞N/AN/AN/AN/A7/14/2025 (Estimated)KRROKorro Bio-$81.17M-$9.44N/AN/AN/AN/A-50.25%-38.48%8/12/2025 (Estimated)KYTXKyverna Therapeutics-$60.37M-$3.38N/AN/AN/AN/A-51.12%-37.91%8/11/2025 (Estimated)SGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%8/13/2025 (Estimated)Latest CURR, SGMT, KYTX, and KRRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CURRCURRENC Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/13/2025Q1 2025KYTXKyverna Therapeutics-$1.21-$1.03+$0.18-$1.03N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million4/14/2025Q4 2024CURRCURRENC Group-$0.04-$0.70-$0.66-$0.70$10.50 million$11.07 million3/27/2025Q4 2024KYTXKyverna Therapeutics-$0.87-$0.88-$0.01-$0.88N/AN/A3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 million3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURRCURRENC GroupN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURRCURRENC GroupN/AN/AN/AKRROKorro BioN/A11.2311.23KYTXKyverna TherapeuticsN/A10.5010.50SGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURRCURRENC Group56.01%KRROKorro Bio13.18%KYTXKyverna Therapeutics18.08%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCURRCURRENC Group17.80%KRROKorro Bio4.60%KYTXKyverna Therapeutics22.00%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURRCURRENC Group246.53 million38.25 millionN/AKRROKorro Bio709.39 million8.86 millionNo DataKYTXKyverna Therapeutics9643.22 millionN/AOptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableCURR, SGMT, KYTX, and KRRO HeadlinesRecent News About These CompaniesSagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner AscletisJune 4 at 5:00 AM | globenewswire.comMillennium Management LLC Buys 499,094 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)June 1 at 3:44 AM | marketbeat.comContrasting Sagimet Biosciences (SGMT) & Its CompetitorsMay 26, 2025 | americanbankingnews.comSagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatmentMay 24, 2025 | investing.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...May 24, 2025 | morningstar.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025May 22, 2025 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Purchased by Bridgeway Capital Management LLCMay 13, 2025 | marketbeat.comRenaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)May 10, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 9, 2025 | finanznachrichten.deSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.comBoothbay Fund Management LLC Has $56,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)May 7, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Baker BROS. Advisors LPMay 6, 2025 | marketbeat.com138,263 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by 683 Capital Management LLCMay 4, 2025 | marketbeat.comSagimet Biosciences announces presentations at EASL Congress 2025April 25, 2025 | markets.businessinsider.comSagimet Biosciences to Present Phase 2b FASCINATE-2 Study Findings on Denifanstat at EASL Congress 2025April 23, 2025 | quiverquant.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 7.11%April 23, 2025 | aaii.comSagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025April 23, 2025 | finance.yahoo.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%April 7, 2025 | aaii.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%March 31, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryGlobalFoundries Stock Hits Bottom: Is a Rebound Coming?By Thomas Hughes | May 10, 2025View GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?By Nathan Reiff | May 10, 2025View Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?Bloomin’ Brands Stock Drops on Weak Guidance and Demand ConcernsBy Chris Markoch | May 9, 2025View Bloomin’ Brands Stock Drops on Weak Guidance and Demand ConcernsCURR, SGMT, KYTX, and KRRO Company DescriptionsCURRENC Group NASDAQ:CURR$0.50 0.00 (-0.97%) As of 01:28 PM EasternCurrenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.Korro Bio NASDAQ:KRRO$12.09 +0.16 (+1.34%) As of 01:24 PM EasternKorro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$2.82 +0.03 (+1.08%) As of 01:17 PM EasternKyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Sagimet Biosciences NASDAQ:SGMT$4.13 +0.50 (+13.77%) As of 01:22 PM EasternSagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
